Outcomes of Surgical Management of Xanthelasma Palpebrarum

Background  Xanthelasma palpebrarum (XP) is a benign disorder manifesting as yellowishcholesterol-laden plaques on the eyelids. This paper presents the outcomes in patients with XPwhohaveundergone surgical excisionasthemainmodalityoftreatment.Methods  Aretrospective reviewof patientswho received sur...

Full description

Bibliographic Details
Main Authors: Hoon Young Lee, Ung Sik Jin, Kyung Won Minn, Young-Oh Park
Format: Article
Language:English
Published: Thieme Medical Publishers, Inc. 2013-07-01
Series:Archives of Plastic Surgery
Subjects:
Online Access:http://e-aps.org/Synapse/Data/PDFData/2023APS/aps-40-380.pdf
Description
Summary:Background  Xanthelasma palpebrarum (XP) is a benign disorder manifesting as yellowishcholesterol-laden plaques on the eyelids. This paper presents the outcomes in patients with XPwhohaveundergone surgical excisionasthemainmodalityoftreatment.Methods  Aretrospective reviewof patientswho received surgery for xanthelasma palpebrarumfrom March 2007 to March 2011 was conducted. Patients were classified into four gradesaccording to the location and extent ofthe lesion,with grade I being the mildest and grade IVbeing the most diffuse. Simple excision was performed in grade I and II lesions, while localflaps and skin graftswere performed in themore advanced grades.Results  Ninety-five cases from March 2007 to March 2011 were included in this study. 66cases (70%), were treated by simple excision. Twenty-four cases (25%) and 5 cases (5%)were treated by simple excision in combination with or without local flaps and skin grafts. Inapproximately 1/4 ofthe patients, orbicularis orismuscle involvementwas observed. 4 patients(4.2%) developed scar contracture postoperatively, which required a secondary procedure.Recurrencewasreported in 3 patients(3.1%).Otherwise. Therewere no otherreports of majorcomplications or disfigurement.Conclusions  We found that for lesions involving the deep dermis and/or muscle, surgicalexcisionwasthemost appropriate therapeutic option
ISSN:2234-6163
2234-6171